Acme Acquisition Corp

The sponsor's cost basis of $0.003 per share is 4,733× lower than the current retail price of $14.20. This reflects the standard SPAC promote structure where sponsors receive founder shares at nominal cost in exchange for sourcing and completing the acquisition.

Lock-up for both sponsor and PIPE investor shares expires on August 12, 2026 — 47 days from investigation date. Historical data from SPAC Research shows that 78% of SPAC sponsors sell within 30 days of lock-up expiry. PIPE investors entered at $10.00/share and are currently in profit at $14.20, with the same lock-up expiry date.

Retail investors buying at current market price of $14.20 have no lock-up restrictions but face potential selling pressure from 14.125M shares (sponsor + PIPE) becoming freely tradeable in 47 days. This represents approximately 38% of total shares outstanding.

Acme Acquisition Corp's investor presentation (Slide 12) references a “$500M revenue pipeline” as a core component of the investment thesis. Cross-referencing this with the S-4 filing (Page 67, Revenue Recognition Policy), the $500M figure includes non-binding Letters of Intent (LOIs), memoranda of understanding, and preliminary discussions that have not progressed to signed contracts.

Per the most recent 10-Q filing, confirmed contracted revenue stands at $12M — a 97.6% gap between the marketed pipeline figure and binding commitments. This gap is not explicitly disclosed in investor-facing materials reviewed.

Three outstanding warrant tranches were identified in the S-1/A filing: (1) 11.5M public warrants at $11.50 strike, (2) 6.6M private placement warrants at $11.50 strike held by the sponsor, and (3) 2.3M working capital warrants at $10.00 strike. If all warrants are exercised, total dilution to existing shareholders is approximately 22% at current share count.

The most recent 10-Q (Q3 2025) contains going-concern language in Note 2: “The Company has incurred significant losses since inception and has a net cash outflow from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern.” The company had $8.4M cash on hand against $6.2M quarterly operating expenses, implying approximately 1.4 quarters of runway without additional capital.

An S-3 shelf registration was filed on January 8, 2026, authorizing up to $150M in additional securities issuance. No pending litigation was found in PACER federal court records or state court databases for the company or its officers in their corporate capacity.

CEO — John R. Mercer: Prior to founding Acme Capital, Mercer served as CEO of Meridian Holdings Inc. (OTC: MRDH) from 2016–2019. PACER records confirm Meridian filed for Chapter 11 bankruptcy protection on September 14, 2019 (Case No. 19-12847, SDNY). The S-4 filing for Acme Acquisition Corp lists Mercer's prior roles but does not reference the bankruptcy proceeding. LinkedIn profile lists Meridian Holdings without mention of outcome.

CFO — Sarah T. Klein: Klein served as VP Finance at Vertex Capital Partners from 2018–2021. SEC EDGAR records show Vertex received an administrative proceeding (AP No. 34-91274) in March 2021 related to record-keeping deficiencies. The matter was settled with a $175,000 fine and neither admitted nor denied findings. Klein was not personally named as a respondent but was the senior finance officer during the period in question. This is not disclosed in Acme investor materials.

Board of Directors: 3 of 5 board members have prior SPAC experience. Director James Whitfield served on the board of Apex Acquisition Corp (APXC), which completed a merger in 2020 and subsequently saw share price decline 71% within 18 months. Director compensation includes 200,000 restricted shares each, vesting upon successful deal completion.

Fully diluted share count including all warrant tranches is approximately 57.4M shares, implying a fully diluted market cap of $815M at $14.20. If warrants are exercised at $11.50 strike, institutional investors gain additional shares below current market, increasing the effective premium paid by retail investors.

For a retail investor buying at $14.20 to break even on a fully diluted basis, the company would need to maintain a market cap above $815M. Given trailing twelve-month revenue of $12M (confirmed), this implies a price-to-revenue multiple of approximately 68×.

Three comparable companies were identified based on matching criteria: same sector (technology/SaaS), similar enterprise value at merger ($400M–$800M), and completed SPAC merger in 2023–2024. All three operated in the B2B software vertical.

CloudBridge (CBRI) was the only comparable that avoided significant decline; it had confirmed contracted revenue of $45M at time of merger (3.7× Acme's current confirmed revenue). Both TechVista and Apex had revenue profiles similar to Acme's at the time of their mergers — heavy reliance on LOI-stage pipeline with limited contracted revenue.

The investment thesis presented by Acme rests on three core assumptions. Each was assessed independently against available evidence:

For the bull case to materialise, all three assumptions must hold. Revenue growth of 80% requires converting a significant portion of the LOI pipeline to binding contracts within the next 12 months. Even with successful product launch (MEDIUM confidence), the revenue growth assumption depends on market adoption timelines that are not yet evidenced in filings.

The combination of LOW confidence on revenue growth and LOW confidence on management execution — given the CEO's prior Chapter 11 history identified in Pillar 4 — means the overall bull case rests on relatively weak foundations. That said, the $2B addressable market (confirmed, Pillar 2) and successful beta programme suggest the product itself has potential if execution aligns.